Oppenheimer Maintains Outperform Rating on Nurix Therapeutics, $32 Target
Oppenheimer maintained its Outperform rating on Nurix Therapeutics with a $32.00 price target, implying 44.4% upside from the Oct. 12 close of $22.16.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.